Ibuprofen 200 & 400 mg Orodispersible tablet

Ibuprofen 200 & 400 mg Orodispersible tablet
Product Description

Rated as the safest non-steroidal anti-inflammatory Drug by spontaneous adverse drug reaction reporting in the UK1, 2.n Prominent analgesic & antipyretic activities particularly useful in the management of pain related to dysmenorrhea, headache, postoperative dental pain and rheumatoid arthritis3.n Ibuprofen among the most prescribed pain-relieving drugs 4.

ATHENA PHARMACEUTIQUES S.A.S

  • FR
  • 2022
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Pharmaceutical company
Primary activities
Finished Formulation products Distributor/Buyer
Specifications
  • Details
    ODT Athena’s technology is a perfect fit for bedridden patients or patients with difficulties in swallowing or chewing conventional solid dosage forms, without need for water at the time of administration.
  • Selling Points
     NSAIDs market size is expected to move from $15.6 billion in 2019 to $24.4 billion by 2027 exhibiting a CAGR of 5.8% during the forecast period4.n Arthritis segment hold 38.0% NSAIDs market share in 2019 and is likely to lead throughout the forthcoming years4.n Ibuprofen market valued at $294.4 million in 2020 and expected to reach $448.0 million by 2026 growing at a CAGR of 6.1% during the forecasted period5

ATHENA PHARMACEUTIQUES S.A.S

  • FR
  • 2022
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Pharmaceutical company
Primary activities
Finished Formulation products Distributor/Buyer

More Products from ATHENA PHARMACEUTIQUES S.A.S (14)

  • Bilastine 10 mg & 20 mg

    Product Bilastine 10 mg & 20 mg

    1. Bilastine is a potent, effective antihistamine, without sedation, without cardiac toxicity, it has absence of metabolism and does not interact with cytochrome P4502.2. In experimental models, Bilastine has shown an excellent dose-dependent activity when administered by oral or intravenous rout...
  • Domperidone 10 mg Orodispersible Tablet

    Product Domperidone 10 mg Orodispersible Tablet

    Selective D2/D3 dopamine antagonist.n Combine prokinetic and anti-emetic activities on gastrointestinal tract making it an ideal agent for treating gastroparesis (postprandial fullness, nausea, vomiting and stomach fullness). Does not cross the blood-brain barrier minimizing CNS adverse events
  • Donepezil 5 & 10 mg OroDispersible Tablet

    Product Donepezil 5 & 10 mg OroDispersible Tablet

    Lesser behaviour deterioration vs. Galantamine14.n Superior Global Responder Rate vs. Galantamine14.n Lower risk of treatment withdrawals for any reason or because of an adverse event for Donepezil vs. Rivastigmine or Galantamine14
  • Esomeprazole 20 & 40 mg Enteric coated pellets in capsules

    Product Esomeprazole 20 & 40 mg Enteric coated pellets in capsules

    First single stereospecific S-isomer of omeprazole less prone to first-pass metabolism1.n Higher bioavailability than omeprazole2.n Superior acid control compared with all other Proton Pump Inhibitors (omeprazole, pantoprazole, lansoprazole & rabeprazole)3, 4, 
  • Etifoxine 50 mg Capsules

    Product Etifoxine 50 mg Capsules

    Anxiolytic effect equivalent to lorazepam, a higher responder rate, and a lower rate of rebound anxiety at treatment discontinuation (one week) in patients receiving etifoxine5.
  • Fenofibrate 160 , 200  & 267 mg

    Product Fenofibrate 160 , 200 & 267 mg

    Fenofibrate is a third generation fibric acid practically insoluble in water, making it challenging to consistently achieve therapeutic levels1, 2. Micronization technology dramatically improves the dissolution rate-limited gastrointestinal absorption.
  • Levocetirizine 5 mg Orodispersible tablet

    Product Levocetirizine 5 mg Orodispersible tablet

    n Levocetirizine efficacy superior to loratadine, desloratadine and fexofenadine3, 4, 5, 6, 7, 8.n 43% saving on the social cost of persistent allergic rhinitis9.n Minimal impairment of memory and psychomotor functioning nor mood changes after acute and sub chronic administration of levocetirizine10.
  • Meloxicam 7.5 mg & 15 mg Orodispersible tablet

    Product Meloxicam 7.5 mg & 15 mg Orodispersible tablet

    Meloxicam appears to have better gastrointestinal tolerance than non-selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) thanks to its preferential inhibition of COX-2 vs. COX-1. The Orodispersible tablets enhance patient compliance, administration without water and accuracy of dosage
  • Prednisolone 1mg & 5mg Orally Disintegrating Tablet

    Product Prednisolone 1mg & 5mg Orally Disintegrating Tablet

    n Prednisolone is highly effective and signifi cantly more effective that Non-Steroidal Anti-Infl ammatory Drugs (NSAIDs) in rheumatoid arthritis and may be used intermittently1.n Prednisolone is the active metabolite of prednisone and prednisone’s effi cacy is related to the patient’s hepatic fu...
  • Prednisolone 1mg & 5mg Orally Disintegrating Tablet

    Product Prednisolone 1mg & 5mg Orally Disintegrating Tablet

    Prednisolone is highly effective and signifi cantly more effective that Non-Steroidal Anti-Infl ammatory Drugs (NSAIDs) in rheumatoid arthritis and may be used intermittently1.n Prednisolone is the active metabolite of prednisone and prednisone’s effi cacy is related to the patient’s hepatic func...
  • Racecadotril 10 & 30 mg sache

    Product Racecadotril 10 & 30 mg sache

    n Racecadotril is a guideline-recommended treatment to alleviate symptoms of acute diarrhoea1, 2, 3. Safety profile is similar to that of placebo. Racecadotril inhibits the degradation of enkephalins, which in turn have potent antisecretory activity but only little effect on motility in the gut i...
  • Secnidazole 2 mg sachet

    Product Secnidazole 2 mg sachet

    Next-generation 5-nitroimidazole prodrug granted priority review by the FDA with longer half-life (17h) allowing for a once-daily dosing.n Secnidazole has similar activity against the range of microorganisms associated with bacterial vaginosis compared to metronidazole or tinidazole whilst sparin...

ATHENA PHARMACEUTIQUES S.A.S resources (1)

  • Video Navigating the Drug Delivery Device Development Process

    The purpose of this section, is to give to the audience some advice and warnings on how to better develop and produce a customized drug delivery medical device, based on our own experience. in fact the pathway for a new drug delivery medical device, is full of the unexpected and sometimes the company has to stop the development phase so they never get to production or they spend a lot more money and time compared to a better path/arrangement. There will be also examples and case studies taken from our own experience. The other purpose of this section, is to show you the advantages of a customer centric and multidisciplinary approach to develop and produce a customized drug delivery device.